Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer is a research paper published in Journal for ImmunoTherapy of Cancer (2021). On theSindex it has a DataRank of 1.3. It has been cited 32 times, with 29 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.524
From this paper's citation signal
Citation Network Contribution
0.793
From 26 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 29 citers.
National Institutes of Health
Grant: P30CA033572
National Cancer Institute
Grant: K12CA001727
National Institutes of Health
Grant: 5P30CA033572-27
Developmental Funds
National Institutes of Health
Grant: 2K12CA001727-16A1
City of Hope Clinical Oncology Career Research Development Program
Fields of Study
Keywords
Sustainable Development Goals